Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, Enrica Morra

Blood (2011) 118 (15): 4079–4085.

https://doi.org/10.1182/blood-2011-05-351833

Published: 2011

Journal Articles

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Marco Montillo, MD, Alessandra Tedeschi, Francesca Ricci, Alfonso Zaccaria, Monica Crugnola, Mauro Spriano, PierAngelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Angelo De Blasio, Eleonora Vismara, Enrica Morra, Valeria Belsito Petrizzi

Blood (2010) 116 (21): 1384.

https://doi.org/10.1182/blood.V116.21.1384.1384

Published: 2010

Journal Articles

Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL): Final Results and Long Term Follow-up.

Umberto Tirelli, MD, Lucia Fratino, Monica Balzarotti, Lilj Uziel, Annalisa Giacalone, Andres Ferreri, Armando Santoro, Michele Spina, MD

Blood (2009) 114 (22): 2684.

https://doi.org/10.1182/blood.V114.22.2684.2684

Published: 2009

Journal Articles

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Eleonora Vismara, MD, Denis Ciapanna, MD, Valeria Belsito Petrizzi, MD, Monica Crugnola, MD, Mauro Spriano, MD, Lilj Uziel, MD, Angelo De Blasio, MD, Pierangelo Spedini, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3133.

https://doi.org/10.1182/blood.V110.11.3133.3133

Published: 2007

Journal Articles

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Alessandro Corso, MD, Silvia Mangiacavalli, MD, Luciana Barbarano, MD, Patrizia Zappasodi, MD, Luciano Banfi, MD, Luigi Montalbetti, MD, Antonio Mazzone, MD, Sergio Fava, MD, Guido Frigerio, MD, Luciano Isa, MD, Sergio Montanara, MD, Daniele Perego, MD, Maria Savarè, MD, Lilj Uziel, MD, Alessandro Vismara, MD, Leonardo Campiotti, MD, Mario Fiumanò, MD, Mario Lazzarino, MD, Enrica Morra, MD

Blood (2006) 108 (11): 3567.

https://doi.org/10.1182/blood.V108.11.3567.3567

Published: 2006

Journal Articles

Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.

Luca Arcaini, Marco Paulli, Sara Burcheri, Emanuela Boveri, Andrea Rossi, Michele Spina, Francesco Passamonti, Mauro Montanari, Andrea Gallamini, Lilj Uziel, Monica Crugnola, Francesca Montanari, Cristiana Pascutto, Enrica Morra, Mario Lazzarino

Blood (2006) 108 (11): 2427.

https://doi.org/10.1182/blood.V108.11.2427.2427

Published: 2006

Journal Articles

Unexpectedly High Incidence of Interstitial Pneumonia in Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Rituximab-CHOP-14 Supported with Pegfilgrastim.

Ercole Brusamolino, MD, Chiara Rusconi, MD, Luigi Montalbetti, MD, Livio Gargantini, MD, Graziella Pinotti, MD, Lilj Uziel, MD, Sergio Fava, MD, Luigi Rigacci, MD, Guido Pagnucco, MD, Guido Frigerio, MD, Mario Fiumano, MD, Luciano Banfi, MD, Francesco Rodeghiero, MD, Giovanni Ucci, MD, Alberto De Paoli, MD, Giuseppe Attardo Parrinello, MD, Enrica Morra, MD, Mario Lazzarino, MD

Blood (2005) 106 (11): 3330.

https://doi.org/10.1182/blood.V106.11.3330.3330

Published: 2005

NARROW

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL): Final Results and Long Term Follow-up.

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.

Unexpectedly High Incidence of Interstitial Pneumonia in Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Rituximab-CHOP-14 Supported with Pegfilgrastim.

Email alerts

ASH Publications

American Society of Hematology

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL): Final Results and Long Term Follow-up.

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.

Unexpectedly High Incidence of Interstitial Pneumonia in Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Rituximab-CHOP-14 Supported with Pegfilgrastim.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only